{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:22:07Z","timestamp":1792801327293,"version":"4.5.0"},"reference-count":152,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023674","name":"Deanship of Scientific Research, King Khalid University","doi-asserted-by":"publisher","award":["RGP2\/257\/45"],"award-info":[{"award-number":["RGP2\/257\/45"]}],"id":[{"id":"10.13039\/501100023674","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Neurodegenerative disorders such as Alzheimer\u2019s disease (AD), Parkinson\u2019s disease (PD), Huntington\u2019s disease (HD), and amyotrophic lateral sclerosis (ALS) are characterized by the progressive degeneration of neuronal structure and function, leading to severe cognitive and motor impairments. These conditions present significant challenges to healthcare systems, and traditional treatments often fail to account for genetic variability among patients, resulting in inconsistent therapeutic outcomes. Pharmacogenomics aims to tailor medical treatments based on an individual\u2019s genetic profile, thereby improving therapeutic efficacy and reducing adverse effects. This focused review explores the genetic factors influencing drug responses in neurodegenerative diseases and the potential of pharmacogenomics to revolutionize their treatment. Key genetic markers, such as the APOE \u03b54 allele in AD and the CYP2D6 polymorphisms in PD, are highlighted for their roles in modulating drug efficacy. Additionally, advancements in pharmacogenomic tools, including genome-wide association studies (GWAS), next-generation sequencing (NGS), and CRISPR-Cas9, are discussed for their contributions to personalized medicine. The application of pharmacogenomics in clinical practice and its prospects, including ethical and data integration challenges, are also examined.<\/jats:p>","DOI":"10.3389\/fphar.2024.1478964","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T04:22:45Z","timestamp":1734668565000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Pharmacogenomics for neurodegenerative disorders - a focused review"],"prefix":"10.3389","volume":"15","author":[{"given":"S. Rehan","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md.","family":"Zeyaullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Suhail","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah M.","family":"AlShahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrhman A. Galaleldin","family":"Altijani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haroon","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Dawria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Mohieldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Shane","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awad Osman Abdalla","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"key":"B1","first-page":"a025503","article-title":"Symptomatic and nonamyloid\/tau based pharmacologic treatment for Alzheimer disease","volume":"6","author":"Aisen","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3233\/JPD-181331","article-title":"Gene therapy for Parkinson's disease, an update","volume":"8","author":"Axelsen","year":"2018","journal-title":"J. Parkinson's Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/S0140-6736(10)61349-9","article-title":"Alzheimer's disease","volume":"377","author":"Ballard","year":"2011","journal-title":"Lancet"},{"key":"B134","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00401-008-0409-8","article-title":"Evaluation of alpha-synuclein immunohistochemical methods used by invited experts","volume":"116","author":"Beach","year":"2008","journal-title":"Acta Neuropathol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.neures.2006.11.012","article-title":"CARD15 variants in patients with sporadic Parkinson's disease","volume":"57","author":"Bialecka","year":"2007","journal-title":"Neurosci. Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1093\/brain\/awv236","article-title":"The preclinical phase of the pathological process underlying sporadic Alzheimer's disease","volume":"138","author":"Braak","year":"2015","journal-title":"Brain"},{"key":"B6","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/gim.2013.113","article-title":"Recommendations for returning genomic incidental findings? We need to talk","volume":"15","author":"Burke","year":"2010","journal-title":"Genet. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1159\/000113695","article-title":"Influence of pharmacogenetic factors on Alzheimer's disease therapeutics","volume":"5","author":"Cacabelos","year":"2008","journal-title":"Neurodegener. Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"133807","DOI":"10.1016\/j.neulet.2018.09.018","article-title":"Pharmacogenomics of Alzheimer's and Parkinson's diseases","volume":"726","author":"Cacabelos","year":"2020","journal-title":"Neurosci. Lett."},{"key":"B9","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1056\/NEJMp1500523","article-title":"A new initiative on precision medicine","volume":"372","author":"Collins","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B10","first-page":"1","article-title":"Drug development in Alzheimer's disease: the path to 2025","volume":"11","author":"Cummings","year":"2019","journal-title":"Alzheimer's Res. and Ther."},{"key":"B140","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1017\/S1041610214001963","article-title":"International psychogeriatric association. Agitation in cognitive disorders: international psychogeriatric association provisional consensus clinical and research definition","volume":"27","author":"Cummings","year":"2015","journal-title":"Int. Psychogeriatr."},{"key":"B11","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","article-title":"Expanded GGGGCC hexanucleotide repeat in noncoding region of C9orf72 causes chromosome 9p-linked FTD and ALS","volume":"72","author":"DeJesus-Hernandez","year":"2011","journal-title":"Neuron"},{"key":"B12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/nature10353","article-title":"Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS\/dementia","volume":"477","author":"Deng","year":"2011","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1258096","DOI":"10.1126\/science.1258096","article-title":"Genome editing. The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"key":"B14","first-page":"1007","article-title":"Biomarkers of dietary intake of fatty acids and risk of myocardial infarction","volume":"69","author":"Drogan","year":"2015","journal-title":"Eur. J. Clin. Nutr."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nature09320","article-title":"Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS","volume":"466","author":"Elden","year":"2010","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41593-017-0059-z","article-title":"Dietary salt promotes neurovascular and cognitive dysfunction through a gut-initiated TH17 response","volume":"21","author":"Faraco","year":"2018","journal-title":"Nat. Neurosci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s13311-013-0244-z","article-title":"Treatment of Huntington's disease","volume":"11","author":"Frank","year":"2014","journal-title":"Neurotherapeutics"},{"key":"B18","first-page":"412","article-title":"Therapeutic genome editing: prospects and challenges","volume":"22","author":"Gaj","year":"2017","journal-title":"Nat. Med."},{"key":"B143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/archneur.58.2.186","article-title":"Synucleinopathies: clinical and pathological implications","volume":"58","author":"Galvin","year":"2001","journal-title":"Arch. Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1212\/WNL.0000000000001315","article-title":"Differential effects of severe vs mild GBA mutations on Parkinson disease","volume":"84","author":"Gan-Or","year":"2015","journal-title":"Neurology"},{"key":"B20","first-page":"186","article-title":"The proteasome: a valuable target for Huntington's disease treatment?","volume":"24","author":"Gao","year":"2018","journal-title":"Trends Mol. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2147\/CIA.S105769","article-title":"Genes associated with Alzheimer's disease: an overview and current status","volume":"11","author":"Giri","year":"2016","journal-title":"Clin. Interventions Aging"},{"key":"B22","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1126\/science.1132814","article-title":"A century of Alzheimer's disease","volume":"314","author":"Goedert","year":"2006","journal-title":"Science"},{"key":"B23","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nrg.2016.49","article-title":"Coming of age: ten years of next-generation sequencing technologies","volume":"17","author":"Goodwin","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"B24","first-page":"273","article-title":"An exploratory study on the influence of apolipoprotein E genotypes in ALS: a population-based study in northern Italy","volume":"348","author":"Guerini","year":"2015","journal-title":"J. Neurological Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa1211851","article-title":"TREM2 variants in Alzheimer's disease","volume":"368","author":"Guerreiro","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrm2101","article-title":"Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide","volume":"8","author":"Haass","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1111\/j.1471-4159.2009.06181.x","article-title":"The amyloid hypothesis for Alzheimer's disease: a critical reappraisal","volume":"110","author":"Hardy","year":"2009","journal-title":"J. Neurochem."},{"key":"B144","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3389\/fpsyg.2017.00697","article-title":"Pathways from trauma to psychotic experiences: a theoretically informed model of posttraumatic stress in psychosis","volume":"8","author":"Hardy","year":"2017","journal-title":"Front Psychol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","article-title":"National Institute on Aging\u2013Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease","volume":"8","author":"Hyman","year":"2012","journal-title":"Alzheimer's and Dementia"},{"key":"B130","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nrn3549","article-title":"Parkinson's disease dementia: convergence of \u03b1-synuclein, tau and amyloid-\u03b2 pathologies","volume":"14","author":"Irwin","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","article-title":"Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade","volume":"9","author":"Jack","year":"2010","journal-title":"Lancet Neurology"},{"key":"B128","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41583-018-0067-3","article-title":"Imaging the evolution and pathophysiology of Alzheimer disease","volume":"19","author":"Jagust","year":"2018","journal-title":"Nat. Rev. Neurosci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1093\/bioinformatics\/btn564","article-title":"SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap","volume":"24","author":"Johnson","year":"2008","journal-title":"Bioinformatics"},{"key":"B31","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1542\/peds.2012-0469","article-title":"The science of early life toxic stress for pediatric practice and advocacy","volume":"131","author":"Johnson","year":"2013","journal-title":"Pediatrics"},{"key":"B32","first-page":"301","article-title":"The Parkinson's disease biomarker program","volume":"19","author":"Kang","year":"2020","journal-title":"Lancet Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/jnc.13632","article-title":"The amyloid cascade hypothesis: are we poised for success or failure?","volume":"139","author":"Karran","year":"2016","journal-title":"J. Neurochem."},{"key":"B34","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1126\/science.1109557","article-title":"Complement factor H polymorphism in age-related macular degeneration","volume":"308","author":"Klein","year":"2005","journal-title":"Science"},{"key":"B35","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1126\/science.aab1328","article-title":"Health care policy. Ten things we have to do to achieve precision medicine","volume":"349","author":"Kohane","year":"2015","journal-title":"Science"},{"key":"B138","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.bbadis.2016.01.009","article-title":"Phenotypic and clinical implications of variants in the dihydropyrimidine dehydrogenase gene","volume":"1862","author":"Kuilenburg","year":"2016","journal-title":"Biochim. Biophys. Acta."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1016\/j.celrep.2017.11.028","article-title":"Large-scale cognitive GWAS meta-analysis reveals tissue-specific neural expression and potential nootropic drug targets","volume":"21","author":"Lam","year":"2017","journal-title":"Cell Rep."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/ng.2802","article-title":"Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease","volume":"45","author":"Lambert","year":"2013","journal-title":"Nat. Genet."},{"key":"B38","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2217\/pme.11.7","article-title":"The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?","volume":"8","author":"Lillie","year":"2011","journal-title":"J. Personalized Med."},{"key":"B39","first-page":"1513.e1","article-title":"BDNF Val66Met, A\u03b2 amyloid, and cognitive decline in preclinical Alzheimer's disease","volume":"35","author":"Lim","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"B40","first-page":"1749","article-title":"Genomic studies in Alzheimer\u2019s disease and the potential of gene therapy","volume":"113","author":"Lovestone","year":"2006","journal-title":"J. Neural Transm."},{"key":"B41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-009-0612-2","article-title":"Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations","volume":"119","author":"Mackenzie","year":"2010","journal-title":"Acta Neuropathol."},{"key":"B42","first-page":"451","article-title":"Alzheimer's disease and neuroimaging","volume":"15","author":"Maki","year":"2010","journal-title":"Front. Biosci."},{"key":"B43","first-page":"420","article-title":"Advances in the genetics of Parkinson's disease","volume":"22","author":"Mammen","year":"2009","journal-title":"Curr. Opin. Neurology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"15056","DOI":"10.1038\/nrdp.2015.56","article-title":"Alzheimer's disease","volume":"1","author":"Masters","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B45","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jalz.2011.05.2243","article-title":"The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers","volume":"7","author":"Mattsson","year":"2011","journal-title":"Alzheimer's and Dementia"},{"key":"B46","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.tips.2007.11.005","article-title":"Functional neuroimaging in schizophrenia: diagnosis and drug discovery","volume":"29","author":"McGuire","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"B133","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21170","article-title":"PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2\/N3) nodal metastases in patients with squamous cell head and neck cancer","volume":"21","author":"Mehanna","year":"2017","journal-title":"Health Technol. Assess."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression","author":"Mehta","year":"2020","journal-title":"Lancet."},{"key":"B47","first-page":"239","article-title":"Neuroimaging and biomarkers in Alzheimer's disease: the changing landscape of diagnostic testing","volume":"23","author":"Miller","year":"2013","journal-title":"Neuropsychol. Rev."},{"key":"B152","first-page":"17","article-title":"Integrating writing with science: Examples from NGSS-aligned instruction, grades K-5","volume":"53","author":"Miller","year":"2020","journal-title":"The California Reader."},{"key":"B48","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41398-020-01173-x","article-title":"Structural diverseness of neurons between brain areas and between cases","volume":"11","author":"Mizutani","year":"2021","journal-title":"Transitional Psychiatry"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","article-title":"National Institute on Aging\u2013Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease","volume":"123","author":"Montine","year":"2012","journal-title":"Acta Neuropathol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.neuropharm.2009.11.010","article-title":"Targeting p38 MAPK pathway for the treatment of Alzheimer's disease","volume":"58","author":"Munoz","year":"2010","journal-title":"Neuropharmacol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/ng.801","article-title":"Common variants at MS4A4\/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease","volume":"43","author":"Naj","year":"2011","journal-title":"Nat. Genet."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","article-title":"Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies","volume":"18","author":"Nalls","year":"2019","journal-title":"Lancet Neurol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.nbd.2011.01.021","article-title":"Autophagy failure in Alzheimer's disease\u2013locating the primary defect","volume":"43","author":"Nixon","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1146\/annurev-neuro-061010-113613","article-title":"Amyloid precursor protein processing and Alzheimer's disease","volume":"34","author":"O\u2019Brien","year":"2011","journal-title":"Annu. Rev. Neurosci."},{"key":"B54","first-page":"241","article-title":"The role of nicotinic acetylcholine receptors in Alzheimer's disease","volume":"326","author":"Oddo","year":"2006","journal-title":"Cell Tissue Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMct1208070","article-title":"Deep-brain stimulation for Parkinson's disease","volume":"367","author":"Okun","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B56","first-page":"302","article-title":"Pharmacological approaches to Alzheimer's disease","volume":"69","author":"Panza","year":"2006","journal-title":"Brain Res. Bull."},{"key":"B57","first-page":"1285","article-title":"Blood-brain barrier delivery","volume":"10","author":"Pardridge","year":"2005","journal-title":"Drug Discov. Today"},{"key":"B58","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1056\/NEJMra0909142","article-title":"Alzheimer's disease","volume":"362","author":"Querfurth","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B59","first-page":"393","article-title":"Molecular and pharmacological perspectives of inhibition of nuclear factor kappaB pathway in Alzheimer's disease","volume":"8","author":"Ray","year":"2011","journal-title":"Curr. Alzheimer Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nrneurol.2011.2","article-title":"Epidemiology of alzheimer disease","volume":"7","author":"Reitz","year":"2011","journal-title":"Nat. Rev. Neurol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/nn.3584","article-title":"State of play in amyotrophic lateral sclerosis genetics","volume":"17","author":"Renton","year":"2014","journal-title":"Nat. Neurosci."},{"key":"B148","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.neuron.2011.09.010","article-title":"A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD","author":"Renton","year":"2011","journal-title":"Neuron."},{"key":"B62","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1212\/01.CON.0000429179.21977.a1","article-title":"New genes and new insights from old genes: update on Alzheimer disease","volume":"19","author":"Ringman","year":"2013","journal-title":"Contin. (Minneap. Minn.)"},{"key":"B63","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1126\/science.1132813","article-title":"100 years and counting: prospects for defeating Alzheimer's disease","volume":"314","author":"Roberson","year":"2006","journal-title":"Science"},{"key":"B64","first-page":"140","article-title":"Huntington\u2019s disease and behavioral alterations: neuroanatomical aspects and therapeutic possibilities","volume":"13","author":"Robins Wahlin","year":"2012","journal-title":"Curr. Drug Targets"},{"key":"B65","first-page":"159","article-title":"Impaired cell proliferation in the subventricular zone in Huntington's disease","volume":"449","author":"Rodr\u00edguez","year":"2009","journal-title":"Neurosci. Lett."},{"key":"B66","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington's disease: from molecular pathogenesis to clinical treatment","volume":"10","author":"Ross","year":"2011","journal-title":"Lancet Neurology"},{"key":"B126","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-0348-8225-5_30","article-title":"Catabolism of amyloid-\u03b2 peptide in brain parenchyma","volume-title":"Neuroscientific basis of dementia","author":"Saido","year":"2001"},{"key":"B67","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/nejmoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B125","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s11910-004-0084-7","article-title":"Cognitive reserve: implications for diagnosis and prevention of Alzheimer\u2019s disease","volume":"4","author":"Scarmeas","year":"2004","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"B68","first-page":"505","article-title":"Alzheimer\u2019s disease","volume":"381","author":"Scheltens","year":"2013","journal-title":"Lancet"},{"key":"B69","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/joim.12191","article-title":"Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014","volume":"275","author":"Schneider","year":"2014","journal-title":"J. Intern. Med."},{"key":"B147","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/7854_2015_4010","article-title":"Clinical and pathological features of Parkinson\u2019s disease","volume":"22","author":"Schneider","year":"2015","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"B70","first-page":"701","article-title":"Pharmacotherapy for Alzheimer's disease","volume":"182","author":"Seitz","year":"2010","journal-title":"CMAJ"},{"key":"B137","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease at 25 years","author":"Selkoe","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"a006189","DOI":"10.1101\/cshperspect.a006189","article-title":"Neuropathological alterations in Alzheimer disease","volume":"1","author":"Serrano-Pozo","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B72","first-page":"295","article-title":"Apolipoprotein E gene polymorphisms and risk of dementia: a meta-analysis","volume":"3","author":"Shanker","year":"2010","journal-title":"Int. J. Clin. Exp. Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B74","first-page":"129","article-title":"Clinical studies in Alzheimer's disease: challenges and future perspectives","volume":"54","author":"Sierksma","year":"2020","journal-title":"Curr. Opin. Pharmacol."},{"key":"B75","first-page":"205","article-title":"Healthy dietary changes in midlife are associated with reduced dementia risk later in life","volume":"58","author":"Sindi","year":"2017","journal-title":"J. Alzheimer's Dis."},{"key":"B141","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1037\/a0034412","article-title":"Metacognition as discrimination: Commentary","volume":"128","author":"Smith","year":"2014","journal-title":"J. Comp. Psychol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jns.2005.11.020","article-title":"Idiopathic neuropathy, prediabetes and the metabolic syndrome","author":"Smith","year":"2006","journal-title":"J. Neurol. Sci."},{"key":"B76","first-page":"462","article-title":"The role of palliative care in the management of dementia","volume":"29","author":"Snow","year":"2021","journal-title":"Am. J. Geriatric Psychiatry"},{"key":"B77","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/joim.12178","article-title":"Advances in the prevention of Alzheimer's disease and dementia","volume":"275","author":"Solomon","year":"2014","journal-title":"J. Intern. Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"eaar3959","DOI":"10.1126\/scitranslmed.aar3959","article-title":"Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease","volume":"10","author":"Southwell","year":"2018","journal-title":"Sci. Transnatl. Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Sperling","year":"","journal-title":"Alzheimer's and Dementia"},{"key":"B80","doi-asserted-by":"publisher","first-page":"111cm33","DOI":"10.1126\/scitranslmed.3002609","article-title":"Testing the right target and right drug at the right stage","volume":"3","author":"Sperling","year":"","journal-title":"Sci. Transl. Med."},{"key":"B127","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","author":"Spillantini","year":"1997","journal-title":"Nature."},{"key":"B81","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1212\/wnl.48.3.626","article-title":"Risk of Alzheimer's disease and duration of NSAID use","volume":"48","author":"Stewart","year":"1997","journal-title":"Neurology"},{"key":"B82","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1021\/np030397v","article-title":"Natural products from endophytic microorganisms","volume":"67","author":"Strobel","year":"2004","journal-title":"J. Nat. Prod."},{"key":"B83","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3233\/JAD-2010-1222","article-title":"Role of oxidative stress in the progression of Alzheimer's disease","volume":"19","author":"Sultana","year":"2010","journal-title":"J. Alzheimer's Dis."},{"key":"B151","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/clpt.2011.34","article-title":"Pharmacogenetics: From bench to byte\u2014An update of guidelines","volume":"89","author":"Swen","year":"2011","journal-title":"Clin Pharmacol Ther."},{"key":"B84","first-page":"567","article-title":"Clinical and preclinical biomarkers for Alzheimer\u2019s disease","volume":"18","author":"Szatmari","year":"2021","journal-title":"Curr. Alzheimer Res."},{"key":"B85","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting huntingtin expression in patients with Huntington's disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.cell.2005.02.008","article-title":"Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective","volume":"120","author":"Tanzi","year":"2005","journal-title":"Cell"},{"key":"B142","doi-asserted-by":"publisher","first-page":"a2154","DOI":"10.4102\/abc.v46i2.2154","article-title":"Evaluating the outcomes and processes of a research-action partnership: The need for continuous reflective evaluation","volume":"46","author":"Taylor","year":"2016","journal-title":"Bothalia."},{"key":"B132","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fnmol.2014.00071","article-title":"Regulation and targeting of enzymes mediating Parkinson\u2019s disease pathogenesis: focus on Parkinson\u2019s disease kinases, GTPases, and ATPases","volume":"29","author":"Taymans","year":"2014","journal-title":"Front. mol. neurosci."},{"key":"B87","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jalz.2013.02.003","article-title":"2013 Alzheimer\u2019s disease facts and figures","volume":"9","author":"Thies","year":"2013","journal-title":"Alzheimer\u2019s and Dementia"},{"key":"B88","first-page":"137","article-title":"Update on the genetics of Parkinson's disease","volume":"5","author":"Thomas","year":"2004","journal-title":"Neurogenetics"},{"key":"B139","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1161\/HYPERTENSIONAHA.119.13714","article-title":"Diagnostic and risk factors for complement defects in hypertensive emergency and thrombotic microangiopathy","volume":"75","author":"Timmermans","year":"2020","journal-title":"Hypertension."},{"key":"B89","first-page":"338","article-title":"Current therapeutic approaches for neurodegenerative diseases","volume":"12","author":"Tobe","year":"2018","journal-title":"Front. Neurosci."},{"key":"B90","first-page":"362","article-title":"The clinical applications of biomarkers in Alzheimer\u2019s disease","volume":"127","author":"Toledo","year":"2013","journal-title":"J. Neurochem."},{"key":"B146","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrneurol.2013.132","article-title":"Advances in the genetics of Parkinson disease","volume":"9","author":"Trinh","year":"2013","journal-title":"Nat Rev Neurol."},{"key":"B91","first-page":"136","article-title":"Aggregation of tau in the brains of patients with Alzheimer\u2019s disease","volume":"10","author":"Trojanowski","year":"2000","journal-title":"Curr. Opin. Neurobiol."},{"key":"B92","first-page":"65","article-title":"Pathological and biochemical studies of Alzheimer\u2019s disease and other tauopathies","volume":"126","author":"Trojanowski","year":"2005","journal-title":"Mech. Ageing Dev."},{"key":"B93","doi-asserted-by":"publisher","first-page":"5858","DOI":"10.3390\/ijms21165858","article-title":"Revisiting the amyloid cascade hypothesis: from anti-a\u03b2 therapeutics to auspicious new ways for Alzheimer's disease","volume":"21","author":"Uddin","year":"2020","journal-title":"Curr. Drug Metab."},{"key":"B94","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1021\/acschemneuro.5b00313","article-title":"TREM2 function in Alzheimer\u2019s disease and neurodegeneration","volume":"17","author":"Ulrich","year":"2016","journal-title":"Nat. Immunol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/gim.2015.117","article-title":"The genetic landscape of Alzheimer disease: clinical implications and perspectives","volume":"18","author":"Van Cauwenberghe","year":"2016","journal-title":"Genet. Med."},{"key":"B96","first-page":"205","article-title":"Neuroinflammation in Alzheimer's disease: therapeutic targets and intervention strategies","volume":"108","author":"Van Dongen","year":"2004","journal-title":"Acta Neuropathol."},{"key":"B97","first-page":"657","article-title":"Abnormal processing of the \u03b2-amyloid precursor protein in Alzheimer's disease","volume":"106","author":"Vassar","year":"2000","journal-title":"J. Clin. Investigation"},{"key":"B129","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1189\/jlb.3MR0416-204R","article-title":"Danger-associated molecular patterns in Alzheimer\u2019s disease","volume":"101","author":"Venegas","year":"2017","journal-title":"J. Leukoc. Biol."},{"key":"B98","first-page":"5","article-title":"Curcumin and Apigenin\u2014novel and promising therapeutics against chronic neuroinflammation in Alzheimer\u2019s disease","volume":"12","author":"Venigalla","year":"2015","journal-title":"Neurotherapeutics"},{"key":"B99","first-page":"19","article-title":"Clinical trials in Alzheimer\u2019s disease: from risk factors to therapies","volume":"58","author":"Vilar","year":"2021","journal-title":"Curr. Opin. Pharmacol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"857292","DOI":"10.1155\/2014\/857292","article-title":"Traditional uses, chemical constituents, and biological activities of Bixa orellana L.: a review","volume":"2014","author":"Vilar Dde","year":"2014","journal-title":"Sci. World J."},{"key":"B101","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1001\/jamapsychiatry.2014.2502","article-title":"Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis","volume":"72","author":"Walker","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"B102","first-page":"335","article-title":"The anti-inflammatory and potentially anti-Alzheimer\u2019s disease mechanisms of curcumin","volume":"4","author":"Wang","year":"2007","journal-title":"Curr. Alzheimer Res."},{"key":"B131","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1128\/MCB.26.9.3390-3400.2006","article-title":"Role for Upf2p phosphorylation in Saccharomyces cerevisiae nonsense-mediated mRNA decay","volume":"26","author":"Wang","year":"2006","journal-title":"Mo. Cell Biol."},{"key":"B103","first-page":"73","article-title":"Tau aggregation and toxicity in tauopathies: insights from protein structure and cell biology","volume":"32","author":"Wang","year":"2016","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jalz.2014.11.001","article-title":"2014 Update of the Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception","volume":"11","author":"Weiner","year":"2015","journal-title":"Alzheimer's and Dementia"},{"key":"B105","first-page":"43","article-title":"The role of cognitive tests in the assessment of dementia","volume":"14","author":"Wesnes","year":"2014","journal-title":"Expert Rev. Neurother."},{"key":"B106","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S1474-4422(16)00062-4","article-title":"Defeating Alzheimer\u2019s disease and other dementias: a priority for European science and society","volume":"15","author":"Winblad","year":"2016","journal-title":"Lancet Neurology"},{"key":"B107","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B136","doi-asserted-by":"crossref","first-page":"104984","DOI":"10.1016\/j.ssci.2020.104984","article-title":"Who is responsible for construction safety in Australia? A STAMP analysis","volume":"132","author":"Woolley","year":"2020","journal-title":"Saf. Sci."},{"key":"B108","first-page":"33","article-title":"Longitudinal studies in Alzheimer\u2019s disease","volume":"6","author":"Wright","year":"2014","journal-title":"Alzheimer's Res. and Ther."},{"key":"B109","doi-asserted-by":"publisher","first-page":"a006346","DOI":"10.1101\/cshperspect.a006346","article-title":"Inflammation in Alzheimer disease\u2014a brief review of the basic science and clinical literature","volume":"2","author":"Wyss-Coray","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B110","first-page":"7","article-title":"Anti-inflammation and anti-amyloidogenic activities of resveratrol","volume":"11","author":"Xie","year":"2010","journal-title":"BMC Neurosci."},{"key":"B111","first-page":"970","article-title":"Tau-targeted therapies in Alzheimer's disease","volume":"22","author":"Yan","year":"2014","journal-title":"Am. J. Geriatric Psychiatry"},{"key":"B150","doi-asserted-by":"publisher","first-page":"e3046","DOI":"10.1038\/cddis.2017.504","article-title":"Neural stem cell populations in the postnatal mammalian brain","volume":"8","author":"Yang","year":"2017","journal-title":"Cell Death Dis."},{"key":"B112","first-page":"51","article-title":"New perspectives on Alzheimer's disease treatment: neurogenesis, mitochondrial therapy, and tau targeting","volume":"98","author":"Yang","year":"2020","journal-title":"J. Neurosci. Res."},{"key":"B113","first-page":"13","article-title":"Mitochondrial pharmacology in Alzheimer\u2019s disease: regulation of mitochondrial function","volume":"2","author":"Yao","year":"2011","journal-title":"Front. Pharmacol."},{"key":"B114","first-page":"904","article-title":"Involvement of astrocytes in Alzheimer's disease pathogenesis and therapeutic implications","volume":"14","author":"Yeung","year":"2020","journal-title":"Front. Neurosci."},{"key":"B115","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.tips.2004.11.007","article-title":"Multifunctional drugs for various CNS targets in the treatment of neurodegenerative disorders","volume":"26","author":"Youdim","year":"2005","journal-title":"Trends Pharmacol. Sci."},{"key":"B116","first-page":"633","article-title":"Fluid biomarkers for mild cognitive impairment and Alzheimer's disease","volume":"126","author":"Zetterberg","year":"2013","journal-title":"Acta Neuropathol."},{"key":"B117","first-page":"237","article-title":"Neuromodulation in neurodegenerative diseases: prospects and challenges","volume":"8","author":"Zhang","year":"2014","journal-title":"Front. Behav. Neurosci."},{"key":"B118","doi-asserted-by":"publisher","first-page":"10873","DOI":"10.1074\/jbc.M608856200","article-title":"Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation","volume":"282","author":"Zhang","year":"2007","journal-title":"J. Biol. Chem."},{"key":"B119","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1750-1326-6-27","article-title":"Biology and pathophysiology of the amyloid precursor protein","volume":"6","author":"Zheng","year":"2011","journal-title":"Mol. Neurodegener."},{"key":"B120","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/s41422-020-00452-y","article-title":"Solution structure of the voltage-gated Tim23 channel in complex with a mitochondrial presequence peptide","volume":"31","author":"Zhou","year":"2021","journal-title":"Cell Res."},{"key":"B121","first-page":"232","article-title":"Tau-targeted therapies for Alzheimer\u2019s disease: from bench to bedside","volume":"21","author":"Zhou","year":"2011","journal-title":"Brain Pathol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nrn3114","article-title":"Neurovascular pathways to neurodegeneration in Alzheimer\u2019s disease and other disorders","volume":"12","author":"Zlokovic","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"key":"B123","first-page":"38","article-title":"Aging of the brain and Alzheimer's disease: the biochemically modified amyloid cascade","volume":"1197","author":"Zs-Nagy","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B124","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1146\/annurev.physiol.64.092501.114547","article-title":"Short-term synaptic plasticity","volume":"64","author":"Zucker","year":"2002","journal-title":"Annu. Rev. Physiology"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1478964\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T04:23:09Z","timestamp":1734668589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1478964\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":152,"alternative-id":["10.3389\/fphar.2024.1478964"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1478964","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,20]]},"article-number":"1478964"}}